Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia
Language English Country Czech Republic Media print-electronic
Document type Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
25363727
DOI
10.5507/bp.2014.051
Knihovny.cz E-resources
- Keywords
- acute leukemia, adhesion molecules, biochip array, cytokines,
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma blood diagnosis MeSH
- Leukemia, Myeloid, Acute blood diagnosis MeSH
- Protein Array Analysis methods MeSH
- Cytokines metabolism MeSH
- Diagnosis, Differential MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Cell Adhesion Molecules metabolism MeSH
- Biomarkers, Tumor metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Cytokines MeSH
- Cell Adhesion Molecules MeSH
- Biomarkers, Tumor MeSH
AIMS: To compare serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) using biochip array technology. METHODS: A total of 15 AML and 15 ALL patients were studied. Serum samples were taken prior to anticancer therapy and were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This approach allows simultaneous detection of multiple analytes from a single sample. T-tests were used for statistical analysis. RESULTS: Comparing cytokine and adhesion molecules levels in newly diagnosed AML and ALL patients, we found significant increase in AML in serum IL-4 (P < 0.0001), IL-2 (P < 0.01), IL-3 (P < 0.05), and significant decrease (P < 0.05) in serum VEGF and VCAM-1. DISCUSSION: Our results indicate that serum profile of cytokines and adhesion molecules differs in newly diagnosed AML and ALL patients. Further studies are needed to establish if these alterations could be used as a clinically relevant biomarker for acute leukemias.
References provided by Crossref.org
The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review
